EGFR

EGFR (epidermal growth factor receptor) is a transmembrane receptor tyrosine kinase, the activation of EGFR contributes to promote cancer cell expansion.

There are different types of EGFR mutations. Among the EGFR mutations that are tested for in lung cancer, there are several rare types that are treated differently than the more common EGFR mutations.

About 16% of lung cancer patients have EGFR mutations, and these patients show a greater response to TKi therapy, such as gefitinib, than to traditional chemotherapies. In contrast, patients without such mutations respond better to conventional drugs.

It can be used for the individualized molecular predisposition of cancer, and assists the individualized therapy for tumor patients.